NCT01885000

Patient-Reported Outcome Of Facial Erythema (PROOF)

Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 92 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the patient-reported outcomes (feedbacks of patients)of a new drug for the treatment of erythema of rosacea (central facial redness). The feedback of patients receiving the active drug will be compared to the feedback of patients receiving the placebo.

Conditions

• Rosacea
• Erythema

Interventions

Type	Name	Description
DRUG	Brimonidine tartrate was applied cutaneously once daily for 8 days.
DRUG	Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.

Timeline

• Start date: 2013-07-01
• Primary completion: 2013-11-14
• Completion: 2013-11-14
• First posted: 2013-06-24
• Last updated: 2021-08-25
• Results posted: 2017-01-13

Locations

14 sites across 3 countries: Germany, Sweden, United Kingdom